Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450847 | 1.00 | MAPT (0.48) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL16634785 | 0.86 | MAPT (0.38) | MAPTALDH1A1LMNATDP1POLB | |
| SCHEMBL14525204 | 0.85 | MAPT (0.49) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL22114715 | 0.80 | MAPT (0.48) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL1277890 | 0.77 | MAPT (0.77) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL11209297 | 0.77 | MAPT (0.57) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL11420051 | 0.77 | MAPT (0.62) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL11548169 | 0.75 | MAPT (0.60) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL11545117 | 0.75 | MAPT (0.60) | MAPTALDH1A1LMNATSHRTDP1 | |
| SCHEMBL11628266 | 0.75 | MAPT (0.55) | MAPTALDH1A1LMNATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4192459-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022031928-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-107382983-B | Synthesis method of medicine for treating leukemia | 扬州市三药制药有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-1641780-B1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PROD INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | TOM NORMA J | 2007-04-19 | — | — | US | disclosed |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | TOM NORMA J | 2007-04-19 | — | — | US | disclosed |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | TOM NORMA J | 2007-04-19 | — | — | US | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183414-B2 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1641780-A1 | PROCESSES FOR THE PREPARATION OF 1- [(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | Pfizer Products Incorporated (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| WO-2004113322-A1 | PROCESSES FOR THE PREPARATION OF 1-[(BENZOIMIDAZOLE-1YL) QUINOLIN-8-YL] PIPERIDIN-4-YLAMINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | MAPT 4456/4885ALDH1A1 3553/4885LMNA 2900/4885 |
| US-20070088032-A1 | Processes for the Preparation of Benzoimidazole Derivatives | CCNI, CCNT1, CCNE1 | MAPT 4057/4885ALDH1A1 292/4885LMNA 2111/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | MAPT 1834/4885ALDH1A1 4420/4885LMNA 3886/4885 |
| US-20050020625-A1 | Processes for the preparation of benzoimidazole derivatives | CCNI, CCNT1, CCNE1 | MAPT 4068/4885ALDH1A1 334/4885LMNA 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.